{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.04","upperLimit":"1.2","value":"1.12"}]}],"title":"Platinum in plasma"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.985","upperLimit":"1.11","value":"1.04"}]}],"title":"Platinum in ultrafiltrate"}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"}],"units":"Participants"}],"description":"AUClast was defined as area under the plasma concentration time curve from time zero to the last measurable concentration. AUClast was calculated using linear/log trapezoidal method. Oxaliplatin was evaluated as total platinum in plasma and platinum in plasma ultrafiltrate. The ratio between geometric LS mean (within Cohort 2) for AUClast on Cycle 1 Day 15 and geometric LS mean (within Cohort 2) for AUClast on Cycle 1 Day 1 for Oxaliplatin has been presented in this outcome measure, which explains the data reported for this outcome measure using measure type as \"Number\".","dispersionType":"90% Confidence Interval","groups":[{"description":"Participants received encorafenib 300 mg QD orally and cetuximab 500 mg/m\\^2 IV infusion for 120 minutes Q2W along with fluorouracil 400 mg/m\\^2 IV bolus then 2400 mg/m\\^2 continuous IV infusion over 46-48 hours Q2W; leucovorin 400 mg/m\\^2 IV infusion for 120 minutes Q2W and oxaliplatin 85 mg/m\\^2 IV infusion for 120 minutes Q2W. Participants received treatment in 28-day cycles.","id":"OG000","title":"SLI: Cohort 2 [EC + mFOLFOX6]"}],"paramType":"NUMBER","populationDescription":"The PK parameter analysis set was analyzed. Here, \"Overall Number of Participants Analyzed\" signifies participants evaluable for this outcome measure. Participants received oxaliplatin in Cohort 2 of SLI, hence data is reported only for Cohort 2 and not for Cohort 1.","reportingStatus":"POSTED","timeFrame":"Cohort 2: Pre-dose (0 hr), 1, 2, 3, 4, 6, 8, and 48 hrs post-dose on Days 1 and 15 of Cycle 1","title":"SLI, Cohort 2: Ratio of AUClast on Cycle 1 Day 15 as Compared to Cycle 1 Day 1 for Oxaliplatin","type":"SECONDARY","unitOfMeasure":"Ratio"}